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The PREDIMED (PREvención con DIeta MEDiterránea) multicenter, randomized, primary 
prevention trial assessed the long-term effects of the Mediterranean diet (MeDiet) on clinical 
events of cardiovascular  disease (CVD). We randomized 7447 men and women at high CVD 
risk into three diets: MeDiet supplemented with extra-virgin olive oil (EVOO), MeDiet 
supplemented with nuts, and control diet (advice on a low-fat diet). No energy restriction and 
no special intervention on physical activity were applied. We observed 288 CVD events (a 
composite of myocardial infarction, stroke or CVD death) during a median time of 4.8 years; 
hazard ratios were 0.70 (95% CI, 0.53-0.91) for the MeDiet+EVOO and 0.70 (CI, 0.53-0.94) 
for the MeDiet+nuts compared to the control group. Respective hazard ratios for incident 
diabetes (273 cases) among 3541 non-diabetic participants were 0.60 (0.43-0.85) and 0.82 
(0.61-1.10) for MeDiet+EVOO and MeDiet+nuts, respectively versus control. Significant 
improvements in classical and emerging CVD risk factors also supported a favorable effect of 
both MeDiets on blood pressure, insulin sensitivity, lipid profiles, lipoprotein particles, 
inflammation, oxidative stress, and carotid atherosclerosis. In nutrigenomic studies beneficial 
effects of the intervention with MedDiets showed interactions with several genetic variants 
(TCF7L2, APOA2, MLXIPL, LPL, FTO, M4CR, COX-2, GCKR and SERPINE1) with 
respect to intermediate and final phenotypes. Thus, the PREDIMED trial provided strong 
evidence that a vegetable-based MeDiet rich in unsaturated fat and polyphenols can be a 
sustainable and ideal model for CVD prevention. 
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Cardiovascular (CV) disease (CVD) is the main cause of worldwide premature mortality. 
Coronary heart disease (CHD) and stroke ranked first and third, respectively, as the leading 
global causes of disability-adjusted years according to the global burden of disease estimates 
for 2010
1
. Furthermore, the projections of mortality from CVD for 2030 are dismal
2,3
 and 
underline the need for preventive strategies as a public health priority. In this context, a high-
quality diet and a healthy lifestyle at middle age are the most important factors for CVD 
prevention
3-7
. Consequently, the diet-heart hypothesis has been a long-standing tenet in CVD 
prevention and nutritional epidemiology during the last 50 years
7-8
. Recently, the relevance of 
overall high-quality food patterns, rather than the focus on single nutrients and foods, has 
emerged as a powerful paradigm to address the inherent complexity of dietary exposures and 
to assess their potential CVD preventive effects. Food patterns can be described as the 
amounts, proportions, combinations or varieties for the consumption of different foods and 
beverages and the frequency with which they are usually consumed. This approach allows the 
assessment of synergistic interactions and cumulative effects among different foods and 
nutrients, preempts confounding by alternative dietary exposures, avoids some problems of 
co-linearity between foods or nutrients and thus provides a strong methodological tool in 
nutritional epidemiology
9-10
. Even though randomized dietary intervention trials are the 
hallmarks for acquiring knowledge on the effects of diet on CVD, most research in the field 
of dietary patterns is observational, with some potential for residual confounding and other 




A weakness of the diet-heart hypothesis is that most of the available experimental research in 















existence of multiple pathways leading from diet to CVD speaks against the simplistic 
approach of giving a high value to changes in any single biomarker. Moreover, the induction 
period can vary for the different pathways in which diverse biomarkers are involved, thus 
limiting the possibility of assessing multiple biomarker combinations at any time point. 
Furthermore, other lesser-known pathways could account for a substantial proportion of 
clinical CVD events. The most sensible approach, therefore, in order to investigate the diet-
heart hypothesis is to use hard clinical CVD events as end-points of randomized controlled 
trials (RCTs). Most feeding trials, however, are usually short term and rarely include clinical 
end-points such as CVD events or death
11
. The PREDIMED trial was designed to overcome 
both the problem of the single-nutrient approach and the limitations of assessing only 
intermediate risk markers. Indeed, the PREDIMED randomized trial used an overall food 
pattern as the intervention and assessed hard CVD events as end-points
12 
providing a high 
level of scientific evidence. 
 
Scientific evidence of the cardio-metabolic benefits of the Mediterranean 
diet 
The abundant and consistent observational evidence that was available to support the benefits 
of the Mediterranean diet (MeDiet) and, specifically, of tree nuts and olive oil, on CV health 
prompted us to choose this traditional dietary model enriched with olive oil or nuts as the 
intervention
13-44
. Table 1 summarizes the results of meta-analyses and systematic reviews 
assessing the effects of MeDiet on different cardiometabolic outcomes. 
The MeDiet is defined as the traditional dietary pattern found in the early 1960s in Greece, 
Southern Italy, Spain and other olive-growing countries of the Mediterranean basin. It is a 















consumption of plant-derived foods (fruit, vegetables, legumes, nuts and seeds, and whole 
grain cereals); frequent but moderate intake of wine (especially red wine), usually with meals; 
moderate consumption of seafood and dairy products (especially yogurt and cheese, but not 
whole milk, butter or cream), poultry and eggs; and low consumption of sweet desserts, red 
and processed meats. In comparison with other healthy patterns, such as the DASH diet, the 
healthy US dietary pattern or the Alternative Healthy Eating Index, the consumption of fruit 
and fish is usually higher in the MeDiet, while the consumption of dairy products tends to be 
lower. In healthy vegetarian food patterns, meat and seafood are not consumed, but eggs and 
dairy are most frequently included. Legumes, nuts/seeds, and processed soy are all higher in a 
healthy vegetarian food pattern than in the healthy U.S.-style or Mediterranean-style patterns. 
A considerable scientific advantage of the MeDiet over other healthy dietary patterns was the 
availability of a previous randomized trial, the Lyon Diet Heart study, conducted in 
myocardial infarction survivors (i.e., it was a secondary prevention trial). It showed that a 




 Our hypothesis when designing the PREDIMED trial was that the MeDiet would be 
superior to a low-fat diet for primary CVD prevention. This hypothesis had never been tested 
previously using a RCT design. 
 
Design and methods of the PREDIMED study 
The PREDIMED study was a primary prevention trial which tested the long-term effects of 
the MeDiet on incident CVD in men and women at high CVD risk aged 55-75 y (men) or 60-
80 y (women). PREDIMED was a multicenter,  nutritional intervention RCT carried out in 
Spain from 2003 to 2011. The study was funded by the official Spanish agency for scientific 
research, Instituto de Salud Carlos III
12















material published together with the final results
46
 provide full details of the study protocol. 
We selected participants from >200 primary care facilities affiliated with 11 recruiting sites. 
All participants were at high risk for CVD, but had no history of previous CVD episodes at 
enrolment. Criteria for recruitment were the presence of either type 2 diabetes  mellitus 
(T2DM) or ≥3 risk factors (smoking, overweight or obesity, hypertension/HTN, 
dyslipidemia/DLP, and family history of early-onset CVD). Participants were randomized 
into one of three diets: 1) MeDiet supplemented with extra-virgin olive oil (EVOO) ;2) 
MeDiet supplemented with nuts; and 3) control diet (advice on a low-fat diet).  
Full-time registered dietitians delivered the intervention. Throughout the study, participants 
attended quarterly individual visits and group sessions in which they were instructed to follow 
the allocated diets. Participants also attended quarterly group sessions where they received 
written material with information on key Mediterranean foods and seasonal shopping lists, 
menus and specific recipes for a typical week. This material was discussed in detail with the 
dietitians. Allotments of EVOO (1 L per week, including a minimum of 50 mL/day for 
participants and the rest for family needs) or mixed nuts (30 g/day: 15 g walnuts, 7.5 g 
almonds and 7.5 g hazelnuts plus extra allocations for the family) were supplied at no cost to 
each participant randomly assigned to the MeDiet groups on a quarterly basis during the 
group sessions with dietitians. Participants in the control diet group attended similar quarterly 
sessions with explanations and written material on the low-fat diet and they received non-food 
gifts in these sessions. The three diets were energy-unrestricted and no intervention on 
physical activity was conducted. 
A validated 14-point MeDiet screener
47
 was used by dietitians as a tool to both assess actual 
adherence to the MeDiet and enhance future adherence. These 14 items were: 















2. Consumption of 4 tablespoons/d of olive oil (including oil used for frying, 
salads, out-of-house meals, etc.) 
3. Consumption of  2 servings/d of vegetables 
4. Consumption of  3 servings/d of fruits  
5. Consumption of <1 serving/d of red meat, hamburger or meat products (ham, 
sausage, etc.)  
6. Consumption of <1 serving/d of butter, margarine, or cream 
7. Consumption of <1 serving/d of sweetened and/or carbonated beverages 
8. Consumption of 1 serving/d of wine  
9. Consumption of  3 servings/week of legumes 
10. Consumption of  3 servings/week of fish or shellfish 
11. Consumption of <3 servings/week of commercial sweets or pastries (not 
homemade), such as cakes, cookies, biscuits or custard 
12. Consumption of  3 servings/week of nuts (including peanuts)  
13. Preferential consumption of chicken, turkey or rabbit meat instead of veal, 
pork, hamburger or sausage 
14. Consumption of  2 servings/week of sofrito, a sauce made with tomato and 
onion, leek or garlic and simmered with olive oil. 
Validated food frequency questionnaires covering 137 foods were collected yearly by the 
dietitians. This repeated collection of dietary data allowed us to use the PREDIMED trial as a 
unique setting for subsequent cohort studies analyzed as a prospective observational follow-




Fasting blood and spot urine were obtained and serum, plasma and DNA samples were saved. 















marker of EVOO consumption and plasma α-linolenic acid as marker of walnut consumption) 
were determined in random sub-samples. 
The pre-specified primary end-point of the trial was incident CVD (a composite of non-fatal 
myocardial infarction/MI, non-fatal stroke or CVD death). This composite event occurred in 
288 participants during a median follow-up of 4.8 years. The trial was neither powered nor 
designed to independently assess each of the three components of the combined end-point. 
Secondary outcomes included total mortality, T2DM, metabolic syndrome (MetS), peripheral 
arterial disease (PAD), atrial fibrillation (AF), neurodegenerative diseases and major cancers. 
An event adjudication committee, whose members were blinded to group allocation, was 
responsible for event ascertainment. All participants provided written informed consent and 
the protocol was approved by the Institutional Review Boards of all participating centers. 
 
Main results of the PREDIMED trial 
We randomized 7447 participants into the three PREDIMED intervention groups. The groups 
were well-balanced with respect to their baseline characteristics and pharmacologic 
treatments. Though small, between-group differences in some baseline characteristics were 
observed, but they were not clinically meaningful. Furthermore, we adjusted all risk estimates 
for these variables. The mean age of participants was 67 years, 57% were women and the 
mean body mass index  was 30 kg/m
2
. The baseline prevalence of diabetes was nearly 50% 
and the prevalence of DLP and HTN was higher than 70% and 80%, respectively. 
Compliance with the intervention in the two MeDiet groups was adequate
48
. Our 
tracking of objective biomarkers in random participant subsamples also indicated compliance 
with the intended dietary intervention. However, the achieved absolute difference in 
adherence to the MeDiet (according to the 14-item screener) between the intervention group 















There were no between-group differences in physical activity during the study. No diet-
related adverse effects occurred. 
We assessed the effect of baseline adherence to the 14-point score with respect to the 
subsequent incidence of the primary CVD end-point during follow-up
49
. As shown in Figure 
1, the effect was remarkable. The multivariable-adjusted hazard ratio for participants with a 




 quintile who scored between 8-9 points was 0.72 (95% 
confidence interval [CI]: 0.55-0.94), and for those with the highest adherence (two upper 
quintiles, scoring 10-14 points) it was 0.47 (CI: 0.35-0.65). 
The observed rates per 1000 person-years for the primary end point were 8.1, 8.0, and 11.2 in 
the MeDiet+EVOO, MeDiet+nuts, and control groups, respectively. The unadjusted hazard 
ratios were 0.70 (CI, 0.53-0.91) for the MeD+EVOO and 0.70 (CI, 0.53-0.94) for the 
MeDiet+nuts. The relative risk reductions, absolute risk reductions and number needed to 
treat are shown in Table 2 after multivariable adjustment for sex, age, adiposity variables, and 
baseline CVD risk factors. No effect on all-cause mortality was apparent. Significant disease 
risk reductions were also observed for incident T2DM (in the subset of participants initially 
free of T2DM)
50,51




. Hence, the 
PREDIMED study showed with a RCT design for the first time that a MeDiet supplemented 
with either EVOO or nuts is useful in the primary prevention of CVD, PAD, AF, and T2DM 
in individuals at high risk. 
A beneficial effect of the intervention on MetS status was also observed in the PREDIMED 
trial
54,55
.In comparison with the control group, participants randomized to either MeDiet were 
more likely to show reversion of MetS, with HR 1.35 (CI 1.15–1.58) for the MeDiet+EVOO, 
and HR 1.28 (CI 1.08–1.51) for the MeDiet+nuts. Similarly, the PREDIMED MeDiet 
interventions were shown to reduce blood pressure and the risk of HTN
56,57















progression of subclinical atherosclerosis, as determined by changes in ultrasound-assessed 




Number of events hypothetically prevented with the Mediterranean diet 
Table 3 shows the number of hard clinical CVD events that could be prevented in a 
hypothetical cohort of 1,000 persons undergoing the nutritional intervention with the MeDiet 
used in the PREDIMED trial. These results suggest that even a modest intervention with the 
MeDiet has the potential to account for a sizable reduction in the number of clinical events in 
a relatively short period of time. 
 
Observational studies and trials in the context of the PREDIMED trial 
Although some authors have suggested that RCTs with hard clinical events as end-points are 
the only solution to circumventing the problems of measurement error inherent to 
observational designs in nutritional epidemiology, trials are far from perfect, and also present 
considerable limitations
10
. These problems include the frequent suboptimal compliance, 
losses to follow-up, and the ethical need to prematurely halt the trial when there is sufficient 
evidence of benefit, even when the number of observed events is lower than anticipated. In 
addition, some degree of contamination of the control group with aspects of the intervention 
intended only to the active intervention arms of the trial is unavoidable. Moreover some 
exposures or outcomes cannot be assessed with RCTs. 
In this context, the symbiosis between properly designed RCTs and large cohort 
studies with appropriate and careful control of potentially confounding variables, and due 
precautions to improve dietary measurements, are currently the best possible option to 
ascertain the health effects of dietary exposures. Adequately designed and tested food 















compared to reference measures. In addition, adjustment for total energy intake, usually 
applying the residuals method along with the use of repeated FFQs in long-term prospective 
cohort studies, further improves their validity estimates
9,10
. 
The availability of validated FFQs of each participant with yearly repeated measurements is a 
unique strength of the PREDIMED trial
60
. Furthermore, biomarker analyses have 
corroborated the validity of our dietary assessment tools
61
. Most follow-up studies have 
collected measurements of dietary intake only at baseline and this is a limitation in nutritional 
epidemiology because diet may change during follow-up.  The PREDIMED study has 
provided a large body of evidence on the associations between diet and diverse health 




Mechanisms of protection by the Mediterranean diet 
CVD protection by the MeDiet can be explained by a beneficial effect on classical and emergent 
CV risk factors56,100-102. Although the underlying mechanisms of protection against CVD by the 





 is likely to be relevant. On one hand, this can be due to their anti-
oxidant capacity, such as cell redox state modulating enzyme systems. On the other hand, 
nutrients have the capacity of modulating gene and protein expression and, subsequently, 
metabolite production. Previous nutrigenomic studies have revealed that the MeDiet has a 
protective effect on the expression of several proatherogenic genes involved in vascular 




















We investigated whether the effects of the MeDiet or its components might differ depending 
on genetic variants. We found several gene-diet interactions in determining both intermediate 
and CVD phenotypes
105-109
. Suffice it to say that we observed that the association of the 
MC4R rs17782313 or the FTO rs9939609 polymorphisms with T2DM were modulated by the 
MedDiet
107
. When adherence to the MedDiet was low (<9 out of 14 points), carriers of the 
variant alleles had higher T2DM risk than wild-type subjects. However, when adherence to 
the MedDiet was high (>=9 points), these associations disappeared. These gene-diet 
interactions remained after adjustment for BMI. Adherence to the MedDiet was found to 
interact with the TCF7L2-rs7903146 (C>T) polymorphism in relation to fasting glucose, total 
cholesterol,low-density lipoprotein cholesterol  and triglycerides
108
. When adherence to the 
MedDiet was low, participants with the TT genotype had higher fasting glucose 
concentrations and lipids than CC+CT individuals but when adherence was high, these 
differences were not apparent. Moreover, TT subjects had a higher stroke incidence in the 
control group compared with CC, whereas the dietary intervention with MedDiet was 
associated with reduced stroke incidence in TT homozygotes but not CC homozygotes
108
. 
Both genetic and epigenetic effects on microRNA target site polymorphisms were also 
analyzed. A gain-of-function microRNA-410 target site polymorphism (rs13702T>C) in the 
lipoprotein lipase gene, interacted with the MedDiet intervention in the association with 
triglyceride levels and stroke incidence
110
. The interplay between genetic and epigenetic 
factors may contribute to better understand some biological mechanisms underlying CVD 
progression. Overall these results highlight the relevance of the multi-level omics approaches 


















The findings from the PREDIMED trial, the Lyon Diet-Heart trial, and many large 
prospective cohorts are fully consistent. These large observational and experimental studies 
are also supported by mechanistic investigations aimed to assess classical and emergent CVD 
risk factors and pathophysiological pathways. Anti-inflammatory effects and reduced 
oxidative stress are very likely explanations for the protection observed in the PREDIMED 
trial. Taken together, these research findings converge, demonstrating that the traditional 
MeDiet offers an affordable, attractive, and easily achievable protection against CVD. 
Importantly, these findings suggest that an overall dietary pattern that is rich in high-
unsaturated fat from natural vegetable sources is preferable for CV health than a low-fat diet. 
In addition, the MeDiet has been shown to effectively control the residual risk observed after 
standard pharmacologic treatment of DLP anomalies and HTN in high-risk individuals. 
Taking into account the advanced age of many participants in the PREDIMED trial and in 
some of the available cohorts, it can be concluded that it is never too late to improve the food 
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Figure 1. Association between baseline adherence to the Mediterranean diet and risk of 
major cardiovascular events (primary end-point) in the PREDIMED study. 
Baseline adherence to the Mediterranean diet (14-point PREDIMED score) and 
incidence of the primary end-point in the PREDIMED trial (a composite of myocardial 
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Table 1. Scientific evidence on the Mediterranean diet.  
Systematic reviews assessing the association between adherence to the Mediterranean 
diet and cardio-metabolic outcomes. 
 
Systematic review N 
(Studies 
) 










trials) Weight loss 
-1.75 kg (-
2.86; -0.64) 
Greater weight loss with 
energy restriction and 
longer follow-up 
 















trials) Risk factors Beneficial 
Reductions in BMI, BP, 
glucose and CRP 
Grosso 201424 























Similar favourable changes 









RR = 0.50 
(0.29-0.85)** 
Significant beneficial 
effects were found for each 
of the metabolic syndrome 
criteria 























RR = 0·81 
(0·73-0·90) 
Quantitative meta-analysis: 
long-term studies were 
fairly homogenous  (I2=0%) 
and showed a stronger risk 








RR =  0.77 
(0.66-0.89) 
Quantitative meta-analysis: 
subgroups by region, 
health status, and degree 
of confounding control 













































MeDiet and its 
components CVD 

























stated MeDiet CVD Beneficial 
Qualitative systematic 
review: the results of the 
PREDIMED trial are 
presented in the context of 
their consistency with 
observational results. 
Whayne 201419 Not 







RR = 0.91 
(0.87-0.95) 



































RR = 0.90 
(0.86-0.94) 
The heterogeneity 
disappeared after removing  
3 studies assessing only 
fatal cases 
Martinez-Gonzalez 
200935 5 MeDiet CVD Beneficial 
Qualitative systematic 
review 
de Lorgeril 200836 Not 







trials CVD No evidence 
The selection of trials 
apparently had little 
connection with the 

















200442 6 MeDiet CHD 








22 MeDiet Stroke 




















The authors support the 
case for the urgent  need 








RR = 0.91 
(0.89-0.94) 































40 35 MeDiet 








A variety of 
effects Beneficial 










review: hard end-points 
were not assessed 
 















(+2/9 points): effects associated with increasing 2 points in a 0 to 9 score of adherence 
to the MeDiet. 
CVD: cardiovascular disease 
CHD: coronary heart disease 
RR: Relative Risk (95% Confidence Intervals) 
WMD: weighted mean difference 
CRP: C-reactive protein 
IL-6: interleukin 6 
ICAM-1: intercellular adhesion molecule 
BMI: body mass index 
BP: blood pressure 
I
2
: index to quantify heterogeneity in meta-analyses, please check Higgins et al. BMJ 
2003;327:557–60. 
*Risk ratios in meta-analyses of epidemiologic studies, usually adjusted for multiple 
confounders, compared the highest versus the lowest category of adherence to the 
MeDiet. Outcome changes describe the mean changes for the MeDiet versus 
comparator diets in meta-analyses of RCTs; only statistically significant changes are 
shown. Values between brackets are 95% confidence intervals. 
**An apparent erratum was corrected. The authors presented the log of hazard ratio 
(95% CI) as -0.69 (-2.16 to -1.16), but this is impossible, the correct upper limit should 















Table 2. Relative Risk Reduction, Absolute Risk Reduction and Number Needed to Treat associated with the PREDIMED primary prevention 
intervention for several hard clinical events (assuming median follow-up = 4.8 years). 
 















Primary CVD end-point 30% (8.0% ; 46%) 1.34% (0.36% ; 2.05%) 75 (49-281)  28% (4.0% ; 46%) 1.25% (0.18% ; 2.05%) 80 (49-562) 
Type 2 diabetes 40% (15% ; 57%) 3.52% (1.32% ; 5.02%) 28 (20-76)  18% (-10% ; 39%) 1.59% (-0.88% ; 3.44%) - 
Peripheral artery disease 64% (35% ; 79%) 1.18% (0.64% ; 1.45%) 85 (69-155)  46% (8% ; 68%) 0.85% (0.15% ; 1.25%) 118 (80-679) 
Atrial fibrillation 38% (12% ; 55%) 1.54% (0.48% ; 2.22%) 65 (45-206)  10% (-23% ; 34%) 0.40% (-0.93% ; 1.37%) - 
 
Fully adjusted estimates for the hazard ratios from Cox regression models were used to compute the Relative Risks (RR).  
The Relative Risk Reduction (RRR) was computed as RRR = (1-RR)%. 
The Absolute Risk Reduction (ARR) was computed taking into account the baseline incidence of events in the control group (I0) after a median 















Table 3. Number of expected prevented cases with the PREDIMED primary prevention intervention for several hard clinical events (median 





Number of prevented cases (95% CI) per 1,000 hypothetical 
participants receiving the PREDIMED MeDiet-intervention 
Primary CVD end-point 13 (4 to 20) 
Type 2 diabetes 26 (7 to 41) 
Peripheral artery disease 10 (6 to 13) 


















Figure 1. Baseline adherence to the Mediterranean diet (14-point PREDIMED score) 
and incidence of the primary end-point in the PREDIMED trial (a composite of 
myocardial infarction, stroke or cardiovascular death). 
Q1-Q5: quintiles. 
